Claudin-16 (Paracellin-1) is a transmembrane tight junction (TJ)
protein originally described as having a critical role in the re-absorption of
magnesium and
calcium in the kidney. This study examined expression of
Claudin-16 in human breast cells and tissues to identify a possible link between expression and aggressiveness in cells and between
Claudin-16 levels and patient prognosis. Insertion of the
Claudin-16 gene into MDA-MB-231 human
breast cancer cells resulted in cells that were significantly less motile and invasive in behavior, with increased adhesion to matrix. These cells also exhibited significantly increased TJ functionality and "tighter" colony morphology. Moreover, growth rates were reduced in both in vitro and in vivo assays (P < 0.002). Frozen sections from
breast cancer primary
tumors (matched
tumor 124 and background 33) were immuno-stained.
RNA was reverse transcribed and analyzed by Q-PCR (standardized using
beta-actin, normalized with
cytokeratin-19 levels). Levels of expression of
Claudin-16 were significantly decreased in node positive
tumors compared to negative (P = 0.016). Expression was significantly lower in patients with node positive
tumors (P = 0.016) and in those who had died from
breast cancer or had general poor prognosis (P < 0.015). Immunohistochemical staining showed decreased expression of
Claudin-16 in
tumor sections (P < 0.00001). In conclusion, forced expression of
Claudin-16 in
breast cancer cells resulted in a less aggressive phenotype and reduced in vivo
tumor volume.
Claudin-16 expression was reduced in human
breast cancer, particularly in patients with aggressive
tumors and high mortality. This suggests that
Claudin-16 plays a role beyond that of an initial
metastasis repressor in this
cancer type.